Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy) -2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof. There is need for (2S)-3-[3-[(2S)-3-(4 -chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, in the form of a drug substance, purified so as to minimize a residual solvent content and having a uniformized specification and a highly favorable workability, and a process for producing the same. Crystalline calcium bis[(2S)-3-[3-[(2S)-3-(4 -chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate], a calcium salt of (2S) -3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, solves the above problem.
1. A crystal of calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropyloxy]phenyl]-2-isopropoxypropionate] represented by formula (I-a):
wherein the crystal of the compound has a powder X-ray diffraction pattern with peaks at diffraction angles (2 θ±0.2°) of 6.6, 8.2, 21.1, and 23.0.
2. The crystal according to claim 1 , wherein the crystal has an infrared absorption spectrum with peaks at wavenumbers (±2 cm −1 ) of 1573 and 2237.
3. The crystal according to claim 1 , wherein the crystal has a solid state nuclear magnetic resonance spectrum with peaks at 13 C chemical shifts (±1 ppm) of 185.1, 180.5, and 158.7.
4. A solid pharmaceutical composition characterized by comprising the crystal according to claim 1 .